Establishment of therapeutic models using oncolytic viruses for gastric cancer
Project/Area Number |
26461992
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Wakayama Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
山上 裕機 和歌山県立医科大学, 医学部, 教授 (20191190)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 癌治療用ウイルス / ヘルペスウイルス / 胃癌 |
Outline of Final Research Achievements |
One of the promising therapeutic strategies for malignancies is an oncolytic virotherapy. We have conducted a study of oncolytic herpes simplex viruses (oHSVs) against gastric cancer. In this project, we examined the antitumor effect of fourth-generation oHSVs, which contains ICP6 gene driven human TERT (telomerase reverse transcriptase) promoter (T-hTERT) and T-SOCS-3 expressing suppressor of cytokine signaling-3. For human gastric cancer cell line, we examined the expression of ribonucleotide reductase (RR) activity and their telomerase activity in gastric cancer cell line, and also evauated the cytotoxicity of T-hTERT and T-SOCS-3. T-hTERT was more effective than T-01 and T-SOCS-3 for all gastric cancer cell lines including MKN1. In addition, we are going to establish the predictive models for therapeutic efficacy using freshly surgical specimens of gastric cancer patients.
|
Report
(4 results)
Research Products
(7 results)